Role of SGLT2I in Patients With Myocardial Infarction

February 7, 2024 updated by: Dongying Zhang

Role of SGLT2I in Diabetic Patients With Myocardial Infarction

Role of sglt2I in diabetic patients with myocardial infarction

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Chongqing
      • Chongqing, Chongqing, China, 400016
        • Recruiting
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Acute myocardial infarction patients with diabetes mellitus

Description

Inclusion Criteria:

  1. Acute myocardial infarction patients
  2. Type 2 diabetics.

Exclusion Criteria:

  1. Patients undergoing coronary artery bypass grafting (CABG).
  2. Severe valvular heart disease.
  3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins.
  4. Previously used SGLT2i.
  5. Severe hepatic and renal insufficiency.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
With SGLT2I
Drug: SGLT2 inhibitor
According to whether SGLT2i was used
Without SGLT2i

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MACE
Time Frame: 24months
cardiovascular death and heart failure and myocardial infarction
24months
Heart failure readmission
Time Frame: 24months
Heart failure readmission
24months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recurrent myocardial infarction
Time Frame: 24months
Recurrent myocardial infarction
24months
cardiovascular death
Time Frame: 24months
cardiovascular death
24months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dongying Zhang

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Estimated)

February 28, 2024

Study Completion (Estimated)

March 31, 2024

Study Registration Dates

First Submitted

January 30, 2024

First Submitted That Met QC Criteria

January 30, 2024

First Posted (Actual)

February 7, 2024

Study Record Updates

Last Update Posted (Actual)

February 8, 2024

Last Update Submitted That Met QC Criteria

February 7, 2024

Last Verified

May 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20230515

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe